Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...
Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...
Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...
Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...
Sanofi Indias standalone net profit jumped 31% Rs 91.3 crore in Q4 FY25 as compared with Rs 69.7 crore in Q4 FY24. Revenue increased 9.7% YoY to Rs 514.9 crore in Q4 FY25. Schaeffler Indias ...
Dividend Stocks 2025: Sanofi India and Schaeffler India share prices were in focus on Thursday as the boards of these companies are set to meet today to consider dividends. Sanofi India Ltd ...
Setting up a free email account has never been easier. You now have many great options that promise lots of storage or convenient features, although there are a few things to keep in mind when ...
Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.
Sanofi and Teva’s inflammatory bowel disease candidate could make €1 billion ($1.05 billion) a year by 2032, Leerink analysts said on Sunday. The blockbuster pro ...
In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results